The FTA unlocks access to the $572.3 billion EU pharmaceuticals and medical devices market, giving a significant boost to the Indian pharmaceutical sector. Saurav Ojha, Co-Founder and Whole-Time Director, Iberia Pharmaceuticals, stated, “The India–EU trade deal can be transformational for healthcare access in India, especially for high-cost specialty drugs and biologics. According to The Financial Express, experts believe the FTA could improve access to therapies such as semaglutide and tirzepatide. Echoing this view, Sheetal Arora, Promoter and CEO, Mankind Pharma Ltd., mentioned, “The India–EU Free Trade Agreement is a significant step for the healthcare and pharmaceutical sector. However, Indian medical device manufacturers have flagged non-tariff barriers as a concern.